CL2018003269A1 - Ácidos carboxílicos para aplicación en la primera infancia. - Google Patents

Ácidos carboxílicos para aplicación en la primera infancia.

Info

Publication number
CL2018003269A1
CL2018003269A1 CL2018003269A CL2018003269A CL2018003269A1 CL 2018003269 A1 CL2018003269 A1 CL 2018003269A1 CL 2018003269 A CL2018003269 A CL 2018003269A CL 2018003269 A CL2018003269 A CL 2018003269A CL 2018003269 A1 CL2018003269 A1 CL 2018003269A1
Authority
CL
Chile
Prior art keywords
application
carboxylic acids
early childhood
pharmaceutically acceptable
carboxylic acid
Prior art date
Application number
CL2018003269A
Other languages
English (en)
Inventor
Ernst Bettina
Original Assignee
Proponent Biotech Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Proponent Biotech Gmbh filed Critical Proponent Biotech Gmbh
Publication of CL2018003269A1 publication Critical patent/CL2018003269A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0014Skin, i.e. galenical aspects of topical compositions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Toxicology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A UNA COMPOSICIÓN FARMACÉUTICA QUE COMPRENDE COMO INGREDIENTE ACTIVO UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO PARA USAR PARA MEJORAR LA FUNCIÓN DE BARRERA CUTÁNEA, DONDE LA COMPOSICIÓN FARMACÉUTICA SE ADMINISTRA A UN LACTANTE. LA INVENCIÓN TAMBIÉN SE REFIERE A UN MÉTODO PARA TRATAR Y/O PREVENIR UNA ENFERMEDAD DE LA PIEL EN UN PACIENTE, EL MÉTODO COMPRENDE ADMINISTRAR UNA CANTIDAD EFECTIVA DE UN ÁCIDO CARBOXÍLICO O UNA SAL FARMACÉUTICAMENTE ACEPTABLE DEL MISMO A UN PACIENTE QUE LO NECESITA.
CL2018003269A 2016-05-17 2018-11-16 Ácidos carboxílicos para aplicación en la primera infancia. CL2018003269A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP16169888 2016-05-17

Publications (1)

Publication Number Publication Date
CL2018003269A1 true CL2018003269A1 (es) 2019-02-22

Family

ID=56014858

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018003269A CL2018003269A1 (es) 2016-05-17 2018-11-16 Ácidos carboxílicos para aplicación en la primera infancia.

Country Status (13)

Country Link
US (1) US20190160030A1 (es)
EP (1) EP3458044A1 (es)
JP (1) JP2019516798A (es)
KR (1) KR20190008236A (es)
CN (1) CN109152755A (es)
AU (1) AU2017266729A1 (es)
BR (1) BR112018072183A2 (es)
CA (1) CA3020558A1 (es)
CL (1) CL2018003269A1 (es)
MX (1) MX2018013474A (es)
RU (1) RU2018143557A (es)
SG (1) SG11201808487UA (es)
WO (1) WO2017198705A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110403914A (zh) * 2019-06-13 2019-11-05 兰溪市立顺生物有限公司 用于儿童早期应用的羧酸

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0617191D0 (en) * 2006-08-31 2006-10-11 York Pharma Plc Improvements in pharmaceutical compositions
AU2007214300B2 (en) * 2007-08-29 2009-11-05 Sunny Pharmtech, Inc. Method for Ameliorating Pruritus
US20130004590A1 (en) * 2011-06-28 2013-01-03 Lin Connie B Zinc oxide/acid containing compositions and methods for treating and/or preventing enzymatic irritation

Also Published As

Publication number Publication date
KR20190008236A (ko) 2019-01-23
WO2017198705A1 (en) 2017-11-23
BR112018072183A2 (pt) 2019-02-12
US20190160030A1 (en) 2019-05-30
RU2018143557A (ru) 2020-06-17
CA3020558A1 (en) 2017-11-23
EP3458044A1 (en) 2019-03-27
MX2018013474A (es) 2019-08-12
JP2019516798A (ja) 2019-06-20
CN109152755A (zh) 2019-01-04
AU2017266729A1 (en) 2018-10-18
SG11201808487UA (en) 2018-10-30

Similar Documents

Publication Publication Date Title
DOP2017000270A (es) Composiciones farmacéuticas tópicas
CO6821938A2 (es) Un compuesto de guanidina o una sal del mismo para el tratamiento de enfermedades relacionadas con vap -1
CL2019003091A1 (es) Terapia de combinación.
GT201500030A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
BR112015029491A2 (pt) derivados de imidazopirrolidinona e seu uso no tratamento de doença
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
ECSP15008695A (es) Combinaciones farmacéuticas que comprenden un inhibidor de b-raf, un inhibidor de egfr y opcionalmente un inhibidor de pi3k-alfa
CR20140086A (es) Tratamientos de combinación para hepatitis c
BR112018069789A2 (pt) medicamento obtido pela combinação do agonista de fxr e arb
ECSP14013200A (es) Una nueva composición terapéutica que contiene apomorfina como principio activo
CY1122899T1 (el) Υδατικη συσταση περιλαμβανουσα παρακεταμολη και ιβουπροφαινη
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
CO2019004004A2 (es) Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico
PE20151746A1 (es) Compuestos biciclicos
CO7121334A2 (es) Formulaciones vesiculares
BR112015025058A2 (pt) composição farmacêutica capaz de controlar facilmente o padrão de dissolução de lacosamida ou de um sal farmaceuticamente aceitável da mesma
CL2018003268A1 (es) Ácidos carboxílicos para tratar/prevenir una enfermedad de la piel.
BR112014015578A2 (pt) composições farmacêuticas tópicas compreendendo bexaroteno e um corticosteróide
AR109012A1 (es) Sistema de administración transdérmica que contiene galantamina o sales de esta
CL2018003269A1 (es) Ácidos carboxílicos para aplicación en la primera infancia.
CL2018003270A1 (es) Una composición farmacéutica que comprende ácido carboxílico para tratar y prevenir congestión nasal.
BR112017007863A2 (pt) composição para o tratamento de condições envolvendo dor muscular
NI201200196A (es) Agentes terapéuticos 976
CL2016001952A1 (es) Formulación farmacéutica tópica que comprende 50 a 2.500 ui/ml de sal de heparina, menos de o igual a 30% v/v de agua, 0% a 30% v/v de un alcohol de cadena inferior; y no menos de 45% v/v de un vehículo miscible en agua seleccionado del grupo que comprende propilenglicol, glicerol, glicofurol, polietilenglicol, o sus mezclas, util en tromboflebitis venosa superficial.
RU2012129115A (ru) Способ лечения острых послеродовых эндометритов у коров